ICR/Cooksey consider single UK fund for health research

22 October 2006

The Institute of Clinical Research (ICR) has met with the Cooksey Review to discuss the new single fund for UK health research.

An outline of the ICR's initial response to the review, which it believes to be "timely and fundamental to the future of health research in the UK," includes that the strength of Medical Research Council and National Health Service R&D is their experience of medical research. By working in partnership with professional bodies such as ICR, expertise can be provided to improve the clinical trial process in the UK, it said.

In terms of the appropriate balance between economic and social benefits, the political climate changes direction with every new minister and improvements are not seen in public health structure due to this, says the ICR. For example, access to advice on regulatory issues and drug development should be in place. There should be improved career development and salary services for NHS and academia to prevent "braindrain" into Pharmaceuticals.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight